The Asia Pacific Uveitis Treatment Market would witness market growth of 6.7% CAGR during the forecast period (2019-2025).
Anti-inflammatory medications are available in the form of eye drops, pills, or injection medicine. Anti-inflammatory medication eye drops may not penetrate well to the back of the eye, so this form of treatment is not recommended for posterior uveitis. In the case of intermediate or posterior uveitis, and if topical corticosteroid has not operated, injections or injections of corticosteroids are used to minimize inflammation. On the other hand, the segment of immunotherapy & targeted therapies is projected to see the highest growth in the market due to a rise in demand for ideal therapies for uveitis treatment. In the market for uveitis treatment, there are immunosuppressant medications such as azathioprine, cyclosporine, methotrexate, mycophenolate, and others.
Corticosteroid treatments have predominantly shaped the bulk of the uveitis market. The Asia-Pacific uveitis market, which is AbbVie’s Humira (adalimumab), currently only provides one targeted treatment. The late-stage uveitis pipeline consists of the Opsiria of Santen and the CLS-TA of Clearside Biomedical, which is predicted to be extremely lucrative and solve some of the unmet needs. These new drugs will broaden the options available for treating patients with uveitis and contribute to overall market growth by introducing new therapeutic pathways, including new drug delivery routes and novel, non-corticosteroid drug molecules.
Based on Drug Class, the market is segmented into Anti-inflammatory, Immunotherapy & Targeted Therapies, Antimicrobial Drugs and Other Drug Class. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online stores. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Alimera Sciences, Inc., Enzo Biochem, Inc., Amgen, Inc., Bausch Health Companies, Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., TopiVert Ltd., and Novartis AG.
Scope of the Study
By Drug Class
• Immunotherapy & Targeted Therapies
• Antimicrobial Drugs
• Other Drug Class
By Disease Type
• Anterior Uveitis
• Posterior Uveitis
• Intermediate Uveitis
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online stores
• South Korea
• Rest of Asia Pacific
• AbbVie, Inc.
• Alimera Sciences, Inc.
• Enzo Biochem, Inc.
• Amgen, Inc.
• Bausch Health Companies, Inc.
• Clearside Biomedical, Inc.
• EyePoint Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.
• TopiVert Ltd.
• Novartis AG
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free
Our reports have been used by over 10K customers, including:
213 pages •
By Asia Market Information & Development Company
• Jun 2020
China’s demand for Respiratory Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...
C-C Chemokine Receptor Type 5 - Pipeline Review, H1 2020 Summary C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes....
Soluble Guanylate Cyclase - Pipeline Review, H1 2020 Summary Soluble Guanylate Cyclase (sGC or EC 188.8.131.52) – Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP....
Type 2 Diabetes - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes – Pipeline Review, H1 2020, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape. Type 2 diabetes is a chronic condition and is...
Malaria - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Malaria – Pipeline Review, H1 2020, provides an overview of the Malaria (Infectious Disease) pipeline landscape. Malaria is a life-threatening blood disease caused by a parasite (Plasmodium)...
The immunotherapy drugs market is projected to grow at a CAGR of 11.0% during the forecast period (2020–2025). The global immunotherapy drugs market is projected to reach USD 274.6 billion by 2025 from USD 163.0 billion in 2020, at a CAGR of 11.0 % during the forecast period. Market growth is primarily driven by the rising demand for immunotherapies...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.